BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34894431)

  • 1. Transcription factors in glioblastoma - Molecular pathogenesis and clinical implications.
    Papavassiliou KA; Papavassiliou AG
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188667. PubMed ID: 34894431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
    Nana AW; Yang PM; Lin HY
    Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma.
    Sun J; Gong X; Purow B; Zhao Z
    PLoS Comput Biol; 2012; 8(7):e1002488. PubMed ID: 22829753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
    Li Q; Dong C; Cui J; Wang Y; Hong X
    J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.
    England B; Huang T; Karsy M
    Tumour Biol; 2013 Aug; 34(4):2063-74. PubMed ID: 23737287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
    BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.
    Wang G; Wang J; Zhao H; Wang J; Tony To SS
    Arch Biochem Biophys; 2015 Aug; 580():84-92. PubMed ID: 26151775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.
    Xu Y; Stamenkovic I; Yu Q
    Cancer Res; 2010 Mar; 70(6):2455-64. PubMed ID: 20197461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR‑378a‑3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17.
    Guo XB; Zhang XC; Chen P; Ma LM; Shen ZQ
    Oncol Rep; 2019 Nov; 42(5):1957-1971. PubMed ID: 31432186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades.
    Allen BK; Stathias V; Maloof ME; Vidovic D; Winterbottom EF; Capobianco AJ; Clarke J; Schurer S; Robbins DJ; Ayad NG
    J Cell Biochem; 2015 Mar; 116(3):351-63. PubMed ID: 25290986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Systems Level Molecular Signatures from Glioblastoma Multiforme Derived Extracellular Vesicles.
    Roy N; Gaikwad M; Bhattacharrya DK; Barah P
    J Mol Neurosci; 2021 Jun; 71(6):1156-1167. PubMed ID: 33231813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
    Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
    Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.